GlucoTrack, Inc. provided updates on initial and long-term preclinical testing for the implantable Continuous Blood Glucose Monitor? (CBGM). The Company announced the successful completion of their first preclinical study of the implantable CBGM.

The study?s objective was to assess implant technique and device safety. In addition, a small sample size of sensors was used to determine device functionality. Although not intended to be an accuracy study, the sensor demonstrates a Mean Absolute Relative Difference (MARD) of 8.1% at Day 30 and 4.5% at Day 60.

The study was completed with no significant adverse effects. The implantable CBGM utilizes an intravascular approach, in which the device is implanted subcutaneously and connected to a lead that is placed directly into a blood vessel. This facilitates continuous blood glucose measurements with zero lag time.

In comparison, many continuous glucose monitoring (CGM) systems measure glucose in the interstitial fluid, which lags behind blood glucose. The approach is based on design elements, implant techniques, and implant tools commonly used for active implantable devices in the cardiovascular space. As a result, it is a recognized, established, and widely utilized implant procedure and device form factor.

This initial preclinical study demonstrates that this approach facilitates a simple implant procedure of approximately 20 minutes. The Company also announced a second milestone: the commencement of long-term preclinical testing on the implantable CBGM. The objective of this study is to assess sensor accuracy and longevity with a refined prototype and larger sample size.

GlucoTrack is committed to commercializing an implantable CBGM with a long-term sensor life, no requirement for an additional wearable component, and a once-only calibration event. The company is preparing for first-in-human studies which are expected to start later this year.